Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Erick Richard Roush Young

Eugene R Hickey

Weimin Liu

Denice Mary Spero

Yancey David Ward

David S Thomson

Sanxing Sun

Robert Sibley

Ronald John Sorcek

Daniel Richard Marshall

Michel Jose Emmanuel

Tina Marie Morwick

Michael Robert Turner

Yunlong Zhang

Leah Lynn Frye

John David Ginn

Renee M Zindell

Hidenori Takahashi

Hossein Razavi

Thomas Martin Kirrane, Jr

Roger John Snow

Usha R Patel

Michael Jason Burke

Younes Bekkali

Qiang Zhang

Xiang Li

Steven Richard Brunette

Asitha Abeywardane

Darren DiSalvo

Sabine K Schlyer

Frank Wu

Jennifer A Kowalski

Lana Louise Smith-Keenan

Georg Dahmann

Pier Francesco Cirillo

Lifen Wu

Mario G Cardozo

Derek Cogan

Charles Lawrence Cywin

Suresh R Kapadia

Zhidong Chen

Matthew Russell Netherton

Anil Kumar Padyana

Lana Louise Smith Keenan

Brian Nicholas Cook

Anthony S Prokopowicz

Jiang-Ping Wu

Sonia Rodriguez

Wang Mao

Fariba Soleymanzadeh

Anjan Saha

Chuk Chui Man

Steven John Taylor

Rajashehar Betageri

Qing Zhang

Di Wu

Michael J Burke

Eugene Richard Hickey

Anthony S Prokopowicz, Iii

Wiemen Liu

George Dahmann

Thomas Martin Kirrane

Michael Jason Bruke

Anthony S Iii Prokopowicz

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, A, Land B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): wherein Rto R, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Benzodioxane inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

Disclosed are compounds of formula (I): wherein Rand Rare defined herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases, cardiovascular disease and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

[object Object]

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them. 

Cathepsin S inhibitors

This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them 

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds 

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds 

Disclosed are compounds of formula (I): wherein the variables R, R, Rand Z are described herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.

Growing community of inventors

Danbury, CT, United States of America

Erick Richard Roush Young